Business Model Breakdown
How ARKG Makes Money
ARKG
Market Cap
$10.27
Annual Revenue
$12.76
Profit Margin
-196.0%
The Short Version
ARKG (ARK Genomic Revolution ETF) is an actively managed exchange-traded fund that provides investors with exposure to companies driving the 'Genomic Revolution.' This involves firms engaged in gene sequencing, gene editing, bioinformatics, and agricultural biology, aiming for long-term capital growth. The fund generates revenue by charging a management fee (expense ratio) on the total assets it manages, essentially making money from investors' capital allocated to its thematic strategy.
Where the Revenue Comes From
Management Fees (Expense Ratio) on Assets Under Management (AUM)
Who buys: Retail investors, institutional investors, and financial advisors seeking exposure to disruptive innovation in genomics and biotechnology through an actively managed portfolio.
Why It Works (Competitive Advantages)
- ✔Active Management & Research Expertise (ARK Invest's specific investment philosophy and research capabilities).
- ✔Thematic Focus (Concentration on disruptive genomic technologies, positioning it for long-term trends).
- ✔Brand Recognition (Cathie Wood's public profile and ARK's track record in identifying innovative companies).
Economic Moat: Narrow (Intangible Assets/IP (Proprietary research and investment framework developed by ARK Invest for identifying disruptive innovation)., Brand Power (The reputation and investor following associated with Cathie Wood and the ARK Invest brand).)
What Our Analysis Says
DVR Score as of June 24, 2026
ARKG presents a compelling high-risk, high-reward opportunity in the genomics sector. Its exceptional 20% YTD return, driven by a favorable FDA regulatory shift, positions it as a top performer. The ETF's strategic focus on disruptive innovation, coupled with ARK Invest's active management, offers significant growth potential as the genomics market expands exponentially. While lacking traditional corporate financials, the fund's strong performance, investor inflows, and leadership highlight its future market leadership potential, aligning with the 10x growth criteria despite its ETF structure. No major red flags or controversies are currently reported.